---
title: "Allarity Therapeutics publishes AACR 2026 posters on stenoparib showing WNT modulation and DRP-linked survival"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283665065.md"
description: "Allarity Therapeutics has published two posters for AACR 2026, highlighting stenoparib's effects on the WNT pathway and its association with improved survival rates. The first poster indicates that high DRP® scores correlate with better overall survival in a phase 2 ovarian cancer trial. The second poster reveals that stenoparib inhibits WNT/β-catenin signaling and colorectal cancer cell growth. The company notes that the DRP® companion diagnostic can help identify patients who are most likely to benefit from the treatment."
datetime: "2026-04-22T12:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283665065.md)
  - [en](https://longbridge.com/en/news/283665065.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283665065.md)
---

# Allarity Therapeutics publishes AACR 2026 posters on stenoparib showing WNT modulation and DRP-linked survival

**Allarity Therapeutics announced AACR posters showing stenoparib’s WNT pathway activity and DRP® association with improved overall survival.**

**Key Highlights:**

-   Published two AACR 2026 posters detailing stenoparib data; both posters now on the company website.
-   Poster shows high stenoparib DRP® scores are associated with enhanced overall survival in a phase 2 ovarian cancer trial.
-   Second poster reports stenoparib blocks WNT/β-catenin signaling and inhibits colorectal cancer cell growth at clinical concentrations.
-   Company emphasizes DRP® companion diagnostic can select patients likeliest to benefit, potentially improving therapeutic outcomes.

Original SEC Filing: Allarity Therapeutics, Inc. \[ ALLR \] - 8-K - Apr. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Allarity Therapeutics Q1 net loss per share narrows](https://longbridge.com/en/news/286612460.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)